Rocket Lab's Neutron Just Slipped Again. Here's the Only Date That Still Matters for Shareholders.

Rocket Lab's Neutron launch timeline may slip to 2027 after management targeted delivery of the rocket to the launch pad only in Q4 2026; shares have fallen 24% over the past two weeks amid repeated delays. The more consequential potential catalyst is Rocket Lab's planned $8 billion acquisition of Iridium, expected to close around mid-2027, adding roughly $884 million of annual revenue at 72% gross margins. Analysts expect Iridium to generate more than $135 million in 2027 GAAP profit and over $313 million in free cash flow, which could make Rocket Lab profitable and free-cash-flow positive earlier than previously expected.

Analysis

The strategic logic is stronger for RKLB's valuation than for its operating model: recurring, high-margin service revenue would reduce dependence on lumpy launch and space-systems milestones, potentially lowering the equity-risk premium. But the market should focus on transaction financing rather than pro forma EBITDA. An $8B acquisition is likely to require meaningful stock issuance, leverage, or both; dilution and interest expense could absorb much of the claimed cash-flow accretion, particularly if closing occurs into a higher-rate or weaker capital-markets environment.

IRDM holders gain a credible path to a strategic-control premium, while RKLB shareholders exchange upside from a differentiated launch platform for execution risk across financing, regulatory approval, and post-close capital allocation. The key second-order issue is customer concentration and procurement behavior: U.S. government and defense customers may value a vertically integrated prime, but commercial satellite operators could prefer launch-provider neutrality. That tension could limit cross-selling assumptions and delay revenue synergies for 12-24 months after close.

Near term, RKLB remains principally a schedule-credibility trade, not a cash-flow trade. A further development slip would matter less to a combined company's eventual revenue mix, but it would weaken RKLB's negotiating leverage and increase the probability of an equity-heavy financing package. Contrarian view: the selloff may be directionally rational if investors are capitalizing a 2027 cash-flow narrative without fully discounting deal funding, yet it may be overdone if management secures committed financing with limited dilution and preserves IRDM's standalone free-cash-flow conversion.

Key Decisions for Investors

• Avoid adding directional RKLB exposure before definitive merger terms disclose consideration mix, committed debt, pro forma leverage, and expected share issuance. Set an alert for financing that implies more than 15% dilution or net leverage above approximately 4.0x EBITDA; either would likely cap multiple expansion despite improved recurring revenue.
• For event-driven exposure, accumulate IRDM only if the implied takeover spread exceeds 10-12% after adjusting for estimated close timing; size as a merger-arbitrage position rather than a standalone telecom holding. Exit if regulatory review extends beyond the stated mid-2027 window or if RKLB funding costs widen materially.
• Use a relative-value structure rather than outright RKLB: long IRDM / short RKLB in dollar-neutral size after definitive terms, provided the transaction is primarily stock-funded. This isolates the likely scarcity value of IRDM's cash flows against RKLB's dilution and development-risk exposure; cover if cash consideration rises materially or Neutron reaches successful flight qualification ahead of expectations.
• For a 6-12 month RKLB catalyst trade, wait for independently verifiable engine-test, stage-integration, and pad-readiness milestones rather than management timeline language. A missed milestone or a downward revision to backlog conversion should invalidate any long thesis; successful integrated testing could support a tactical re-rating even before launch.